Objective:To investigate the clinical efficacy of different postoperative drug treatments for patients with stage Ⅳ endometriosis.Methods:A retrospective analysis was conducted on 100 patients with a recent need for fertility who underwent fertility-preserving surgery and were pathologically confirmed to have endometriosis after surgery at the Department of Gynecology of The First Affiliated Hospital of Bengbu Medical University between January 2020 and June 2023. Based on the different adjuvant drugs used for postoperative treatment, the patients were divided into two groups: the leuprolide group and the dienogest group, with 50 patients in each group. The therapeutic effects of the two groups were compared, including changes in sex hormone levels and severity of dysmenorrhea after treatment compared with before treatment. Additionally, pregnancy rate 1 year after surgery and the occurrence of adverse reactions were also monitored.Results:After treatment, the serum levels of estradiol, luteinizing hormone, and follicle-stimulating hormone in the dienogest group were (35.77 ± 6.28) ng/L, (0.50 ± 0.03) IU/L, and (3.90 ± 0.32) IU/L, respectively, and they were (23.36 ± 6.09) ng/L, (0.30 ± 0.02) IU/L, and (2.68 ± 0.28) IU/L, respectively in the leuprolide group. All these measurements were significantly lower than those recorded before treatment in the corresponding group ( t = 40.15, 112.95, 36.25, 27.87, 124.87, 75.86, all P < 0.05). After surgery, the Visual Analog Scale score in the dienogest group was significantly lower than that in the leuprolide group ( t = -11.50, P < 0.05). Within 1 year after surgery, the pregnancy rate in the dienogest group was significantly higher than that in the leuprolide group (χ2 = 3.90, P < 0.05). Conclusion:Compared with postoperative intervention using leuprolide, dienogest as a postoperative drug therapy for patients with stage IV endometriosis demonstrated greater effectiveness in improving fertility and reducing the severity of dysmenorrhea.

Objective:To investigate the clinical efficacy of different postoperative drug treatments for patients with stage Ⅳ endometriosis.Methods:A retrospective analysis was conducted on 100 patients with a recent need for fertility who underwent fertility-preserving surgery and were pathologically confirmed to have endometriosis after surgery at the Department of Gynecology of The First Affiliated Hospital of Bengbu Medical University between January 2020 and June 2023. Based on the different adjuvant drugs used for postoperative treatment, the patients were divided into two groups: the leuprolide group and the dienogest group, with 50 patients in each group. The therapeutic effects of the two groups were compared, including changes in sex hormone levels and severity of dysmenorrhea after treatment compared with before treatment. Additionally, pregnancy rate 1 year after surgery and the occurrence of adverse reactions were also monitored.Results:After treatment, the serum levels of estradiol, luteinizing hormone, and follicle-stimulating hormone in the dienogest group were (35.77 ± 6.28) ng/L, (0.50 ± 0.03) IU/L, and (3.90 ± 0.32) IU/L, respectively, and they were (23.36 ± 6.09) ng/L, (0.30 ± 0.02) IU/L, and (2.68 ± 0.28) IU/L, respectively in the leuprolide group. All these measurements were significantly lower than those recorded before treatment in the corresponding group ( t = 40.15, 112.95, 36.25, 27.87, 124.87, 75.86, all P < 0.05). After surgery, the Visual Analog Scale score in the dienogest group was significantly lower than that in the leuprolide group ( t = -11.50, P < 0.05). Within 1 year after surgery, the pregnancy rate in the dienogest group was significantly higher than that in the leuprolide group (χ2 = 3.90, P < 0.05). Conclusion:Compared with postoperative intervention using leuprolide, dienogest as a postoperative drug therapy for patients with stage IV endometriosis demonstrated greater effectiveness in improving fertility and reducing the severity of dysmenorrhea.

To solve the problem of precise positioning of carp brain tissue coordinates, it is proposed in this paper for a method for transforming the coordinates of magnetic resonance imaging of carp brain tissue into the coordinates of electrode implantation using a brain stereotaxic apparatus. In this study, the 3.0T magnetic resonance imaging instrument was used to scan the carp brain. We independently established the three-dimensional positioning coordinate system of the brain, the three-dimensional coordinate assistance system of skull surface and the three-dimensional coordinate assistance system in brain tissue. After two coordinate transformations, the magnetic resonance image coordinates of the brain electrodes implantation sites were converted into the three-dimensional stereotactic coordinate system to guide the electrodes implantation. The experimental groups were divided into two groups, A and B. Group A was the group of magnetic resonance imaging apparatus combining with the brain stereotaxic apparatus, and group B was the group of brain atlas combining with the brain stereotaxic apparatus. Each group had 20 tails of carps ( = 20). This two methods were used to implant the electrodes into the cerebellar motor area. The underwater experiments of the carp robots were carried out to test the two methods. The results showed that the accuracy of the implanted electrodes were 90% in group A and 60% in group B. The success rate of group A was significantly higher than that of group B ( < 0.05). Therefore, the new method in this paper can accurately determine the coordinates of carp brain tissue.

OBJECTIVE:To observe the antiviral effects of Qingre jiedu soft capsule(ADSC)against influenza A H1N1 virus in vivo,and to provide a experimental support for clinical therapy of influenza A H1N1 virus. METHODS:BALB/c mice were ran-domly divided into normal control group,model control group,positive drug high-dose,medium-dose and low-dose groups [oselta-mivir phosphate capsule,0.04,0.02,0.01 g/(kg·d)] and ADSC high-dose,medium-dose and low-dose groups [1.5,0.75,0.375 g/(kg·d)].Except for normal control group,others groups were given influenza A H1N1 virus with titer 1.6×10-5.2 via nasal cavity to induce poisoned mice model;6-8 h after modeling,they were given relevant medicine intragastrically,once a day,for 5 days. After medication,the change of body weight within 7 d were observed in mice;the mortality and death prevention rate within 15 d,mean survival days(MSDs)were calculated in mice.Other mice were selected and grouped,and they were given same drugs as above. 8 h after last medication,lung index and inhibition rate of lung index were determined in mice.RESULTS:In model control group,the body weight of mice decreased significantly since 5th day,and mice death was beginning to occur since 8th day(mortal-ity of 85.7% within 15 d);the lung index was increased significantly compared to normal control group (P<0.01). Both ADSC and oseltamivir phosphate capsule could slow down the decrease of body weight in mice,decreased the mortality and lung index of mice,and prolonged MSDs;the MSDs of mice in ADSC high-dose,positive drug high-dose and medium-dose groups were signifi-cantly higher than model control group(P<0.05),and lung index was significantly lower than model control group except that of ADSC low-dose group(P<0.05). CONCLUSIONS:ADSC has certain antiviral effect against influenza A H1N1 virus in vivo.

Objective To compare the difference of echocardiography and magnetic resonance imaging (MRI) in measurement of cardiac function in patients with dilated cardiomyopathy (DCM).Methods Totally 41 patients with DCM underwent echocardiography and MRI to measure cardiac function,the parameters included left ventricular end-diastolic volume (LVEDV),end systolic volume (LVESV),left ventricular ejection fraction (LVEF) and stroke volume (SV).The vertical long axis (VLA),horizontal long axis (HLA) and short axis (SA) of heart were measured by echocardiography.The differences of echocardiography and MRI were compared by linear regression and linear correlation.Results ①The value of LVEDV and LVESV obtained by the two methods:the value of LVEDV [(262.6 ± 117.0) ml] and LVESV [(196.4 ± 109.8) ml] obtained by MRI were higher than those of echocardiography [(211.4 ± 90.6),(216.5 ± 71.5),(219.1 ± 80.1) ml;(153.3 ± 76.1),(153.9 ± 54.1),(157.0 ± 61.1) ml,all P ＜ 0.05].②The value of SV and LVEF obtained by the two methods:the value of SV[(66.2 ± 21.3) ml] obtained by MRI was higher than that of echocardiography VLA [(58.1 ± 14.4) ml,P ＜ 0.05].The value of LVEF [(25.2 ±7.2)％] obtained by MRI was lower than those of echocardiography HLA and echocardiography SA [(28.9 ± 6.1)％,(28.3 ± 6.1)％,all P ＜ 0.05].③The value of LVEDV and LVESV obtained by echocardiography SA were associated with those obtained by MRI (r =0.785,0.653,all P ＜ 0.05).The value of LVEF obtained by echocardiography VLA was associated with it obtained by MRI (r =0.690,P ＜ 0.05).The value of SV obtained by echocardiography HLA and echocardiography SA were associated with those obtained by MRI (r =0.734,0.701,all P ＜ 0.05).Conclusion There are differences in accuracy and reliability using echocardiography and MRI when measuring dilated cardiomyopathy heart function,which must be treated differently.

OBJECTIVEOur study aims to evaluate the antiviral effects of Ouyi antipyretic detoxicate soft capsule against influenza A virus H1N1 in vivo, so as to find an effective Chinese medicinal formulae for the treatment of the virus infection, which may lay a theoretical foundation for clinic treatment of patient infected with Influenza A Virus H1N1.

METHODWith the observation of cytopathic effect (CPE) that induced by virus ,we investigated viral inhibition rate by MTT colorimetric assay and valued antiviral activity of drugs by therapeutic index (TI) . Meanwhile, Oseltamivir phosphate capsule (Tamiflu) was used as positive control , we carried out experiments through the three ways of preventive effect, direct inactivation and propagation inhibition.

RESULTOuyi antipyretic detoxicate soft capsule could effectively inhibit cytopathic effect (CPE) that induced by Influenza A Virus H1N1. The preventive effect, direct inactivation , and inhibition of endogenous multiplication of Ouyi antipyretic detoxicate soft capsule and Tamiflu against influenza A virus H1N1 were observed. And three types of action therapeutic index (TI) from Ouyi antipyretic detoxicate soft capsule were (15.5 +/- 0.71), (0.55 +/- 0.071), (6.4 +/- 1.27) severally, comparing Tamiflu with (0.4 +/- 0.14), (1.88 +/- 0.29), (4.6 +/- 0.15), respectively.

CONCLUSIONOuyi antipyretic detoxicate soft capsule showed more remarkable preventive effect than Tamiflu in vitro (P<0.01). The possible mechanism of the antiviral activity observed in our study might be the protection of the MDCK cells from viral infection by inhibiting the viral absorption. We need a further study to certify three effects in vivo.

Animals ; Antipyretics ; pharmacology ; Antiviral Agents ; pharmacology ; Capsules ; Cell Line ; Dogs ; Influenza A Virus, H1N1 Subtype ; drug effects ; Inhibitory Concentration 50

In order to evaluate the anti-influenza virus activity of the effective monomer from Folium Isatidis (FI) in vivo, we established mice model with viral pneumonia and divided them into 3 different dose groups, then observed their lung indexes, pulmonary pathological changes, pulmonary virus hemagglitination titers, living time and death rates. The results showed that the monomer could reduce the pulmonary index from 2.64 to 1.93, 1.63 and 1.40 (P<0.01) and decrease the hemagglitination titer from 1.15 to 0.84, 0.70 and 0.59 (P<0.01). In addition,the living time from 5.1d to 6.5d, 8.4d and 8.9d respectively(P<0.01). The high dose (75 mg/kg/d) has the similar effect with 100 mg/kg/d dose of virazole(P>0.05), and more effective than 200 mg/kg/d dose of antiviral liquor (P<0.05).